{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T05:02:32Z","timestamp":1768712552440,"version":"3.49.0"},"reference-count":50,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Cyclopeptidic chemotherapeutic prodrugs (cPCPs) are macromolecular protease-sensitive doxorubicin (DOX) prodrugs synthesized from a cyclodecapeptidic scaffold, termed Regioselectively Addressable Functionalized Template (RAFT). In order to increase the chemotherapeutic potential of DOX and limit its toxicity, we used a Cathepsin B (Cat B)-sensitive prodrug concept for its targeted release since this enzyme is frequently overexpressed in cancer cells. Copper-free \u201cclick\u201d chemistry was used to synthesize cPCPs containing up to four DOX moieties tethered to the upper face of the scaffold through a Cat B-cleavable peptidic linker (GAGRRAAG). On the lower part, PEG 5, 10 and 20 kDa and a fifth peptidyl DOX moiety were grafted in order to improve the solubility, bioavailability and pharmacokinetic profiles of the compound. In vitro results on HT1080 human fibrosarcoma cells showed that cPCPs display a delayed action that consists of a cell cycle arrest in the G2 phase comparable to DOX alone, and increased cell membrane permeability.<\/jats:p>","DOI":"10.3390\/molecules25184285","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T10:22:23Z","timestamp":1600424543000},"page":"4285","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cathepsin B-Cleavable Cyclopeptidic Chemotherapeutic Prodrugs"],"prefix":"10.3390","volume":"25","author":[{"given":"Viktorija","family":"Herceg","sequence":"first","affiliation":[{"name":"Laboratory of Pharmaceutical Technology, School of Pharmaceutical Sciences, ISPSO, University of Geneva, Rue Michel-Servet 1, CH-1211 Geneve, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5225-1256","authenticated-orcid":false,"given":"Jordan","family":"Bouilloux","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaceutical Technology, School of Pharmaceutical Sciences, ISPSO, University of Geneva, Rue Michel-Servet 1, CH-1211 Geneve, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolina","family":"Janikowska","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaceutical Technology, School of Pharmaceutical Sciences, ISPSO, University of Geneva, Rue Michel-Servet 1, CH-1211 Geneve, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6598-9521","authenticated-orcid":false,"given":"Eric","family":"All\u00e9mann","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaceutical Technology, School of Pharmaceutical Sciences, ISPSO, University of Geneva, Rue Michel-Servet 1, CH-1211 Geneve, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1087-1032","authenticated-orcid":false,"given":"Norbert","family":"Lange","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaceutical Technology, School of Pharmaceutical Sciences, ISPSO, University of Geneva, Rue Michel-Servet 1, CH-1211 Geneve, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/polc.5070510111","article-title":"Structure and Properties of Pharmacologically Active Polymers","volume":"51","author":"Ringsdorf","year":"1975","journal-title":"J. Polym. Sci. Polym. Symp."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","article-title":"Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review","volume":"65","author":"Maeda","year":"2000","journal-title":"J. Control. Release"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrd1088","article-title":"The dawning era of polymer therapeutics","volume":"2","author":"Duncan","year":"2003","journal-title":"Nature Rev. Drug Discov."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1021\/jo0525480","article-title":"Chemoselectively addressable template: A valuable tool for the engineering of molecular conjugates","volume":"71","author":"Garanger","year":"2006","journal-title":"J. Org. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/pro.5560011017","article-title":"Total chemical synthesis, characterization, and immunological properties of an MHC class I model using the TASP concept for protein de novo design","volume":"1","author":"Tuchscherer","year":"1992","journal-title":"Protein Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/bip.360321004","article-title":"Molecular dynamics conformational search of six cyclic peptides used in the template assembled synthetic protein approach for protein de novo design","volume":"32","author":"Floegel","year":"1992","journal-title":"Biopolymers"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1034\/j.1399-3011.1999.00120.x","article-title":"Extending the concept of template-assembled synthetic proteins","volume":"54","author":"Tuchscherer","year":"1999","journal-title":"J. Peptide Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s000180050105","article-title":"Non-native architectures in protein design and mimicry","volume":"53","author":"Mutter","year":"1997","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1039\/B517706E","article-title":"Multivalent RGD synthetic peptides as potent alphaVbeta3 integrin ligands","volume":"4","author":"Garanger","year":"2006","journal-title":"Org. Biomol. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1002\/cbic.200800327","article-title":"Synthesis and biological characterisation of targeted pro-apoptotic peptide","volume":"9","author":"Foillard","year":"2008","journal-title":"Chembiochem"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1039\/B817251J","article-title":"Targeted delivery of activatable fluorescent pro-apoptotic peptide into live cells","volume":"7","author":"Foillard","year":"2009","journal-title":"Org. Biomol. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5730","DOI":"10.1021\/ja049926n","article-title":"Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis","volume":"126","author":"Boturyn","year":"2004","journal-title":"J. Am. Chem. Soc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1007\/s00259-007-0497-z","article-title":"In vivo imaging of tumour angiogenesis in mice with the alpha(v)beta (3) integrin-targeted tracer 99mTc-RAFT-RGD","volume":"34","author":"Sancey","year":"2007","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1039\/c0ob00070a","article-title":"Application of click-click chemistry to the synthesis of new multivalent RGD conjugates","volume":"8","author":"Galibert","year":"2010","journal-title":"Org. Biomol. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1016\/j.bmcl.2010.07.114","article-title":"RGD-cyclam conjugate: Synthesis and potential application for positron emission tomography","volume":"20","author":"Galibert","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1021\/bc050010v","article-title":"Chemoselective assembly and immunological evaluation of multiepitopic glycoconjugates bearing clustered Tn antigen as synthetic anticancer vaccines","volume":"16","author":"Grigalevicius","year":"2005","journal-title":"Bioconjugate Chem."},{"key":"ref_17","first-page":"224","article-title":"RAFT Nano-constructs: Surfing to biological applications","volume":"14","author":"Boturyn","year":"2008","journal-title":"J. Pept. Sci. Off. Publ. Eur. Pept. Soc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","article-title":"Doxorubicin pathways: Pharmacodynamics and adverse effects","volume":"21","author":"Thorn","year":"2011","journal-title":"Pharm. Genom."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharm. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/0005-2787(80)90073-8","article-title":"The interaction of daunorubicin and doxorubicin with DNA and chromatin","volume":"607","author":"Zunino","year":"1980","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF00686403","article-title":"Doxorubicin inhibits human DNA topoisomerase I","volume":"30","author":"Foglesong","year":"1992","journal-title":"Cancer Chemother Pharm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2174\/1568011013354723","article-title":"Anthracyclines: Selected new developments","volume":"1","author":"Binaschi","year":"2001","journal-title":"Curr. Med. Chem. Anticancer Agents"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1096\/fasebj.13.2.199","article-title":"Role of iron in anthracycline cardiotoxicity: New tunes for an old song?","volume":"13","author":"Minotti","year":"1999","journal-title":"FASEB J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/0014-5793(93)81815-H","article-title":"Doxorubicin-induced oxygen free radical formation in sensitive and doxorubicin-resistant variants of rat glioblastoma cell lines","volume":"326","author":"Benchekroun","year":"1993","journal-title":"FEBS Lett."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.2042-7158.2012.01567.x","article-title":"Doxorubicin: An update on anticancer molecular action, toxicity and novel drug delivery systems","volume":"65","author":"Tacar","year":"2013","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0301-4622(98)00150-1","article-title":"Deciphering the fluorescence signature of daunomycin and doxorubicin","volume":"73","author":"Karukstis","year":"1998","journal-title":"Biophys. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2174\/0929867013373994","article-title":"Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines","volume":"8","author":"Perego","year":"2001","journal-title":"Curr. Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11936-014-0315-4","article-title":"Anthracycline-induced cardiotoxicity: A review of pathophysiology, diagnosis, and treatment","volume":"16","author":"Raj","year":"2014","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3892\/ijo.2012.1754","article-title":"Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review)","volume":"42","author":"Zhong","year":"2013","journal-title":"Int. J. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cccn.2003.12.016","article-title":"Cysteine proteases as disease markers","volume":"342","author":"Berdowska","year":"2004","journal-title":"Clin. Chim. Acta"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1515\/BC.2004.132","article-title":"Cysteine cathepsins in human cancer","volume":"38","author":"Jedeszko","year":"2004","journal-title":"Biol. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nrc4027","article-title":"Cysteine cathepsin proteases: Regulators of cancer progression and therapeutic response","volume":"15","author":"Olson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1039\/b901970g","article-title":"Cu-free click cycloaddition reactions in chemical biology","volume":"39","author":"Jewett","year":"2010","journal-title":"Chem. Soc. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1021\/mp100269f","article-title":"Doxorubicin as a molecular nanotheranostic agent: Effect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasound-mediated intracellular delivery and nuclear trafficking","volume":"7","author":"Mohan","year":"2010","journal-title":"Mol. Pharm."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1039\/c9pp90053e","article-title":"Correction: Cyclopeptidic photosensitizer prodrugs as proteolytically triggered drug delivery systems of pheophorbide A: Part II\u2014Co-loading of pheophorbide A and black hole quencher","volume":"18","author":"Bouilloux","year":"2019","journal-title":"Photochem. Photobiol. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1039\/c9pp90052g","article-title":"Correction: Cyclopeptidic photosensitizer prodrugs as proteolytically triggered drug delivery systems of pheophorbide A: Part I\u2014Self-quenched prodrugs","volume":"18","author":"Bouilloux","year":"2019","journal-title":"Photochem. Photobiol. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1021\/bc040241m","article-title":"PEG-doxorubicin conjugates: Influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity","volume":"16","author":"Veronese","year":"2005","journal-title":"Bioconjug. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.neuron.2006.07.027","article-title":"Antiamyloidogenic and neuroprotective functions of cathepsin B: Implications for Alzheimer\u2019s disease","volume":"51","author":"Zhou","year":"2006","journal-title":"Neuron"},{"key":"ref_39","first-page":"455","article-title":"Fluorescent, internally quenched, peptides for exploring the pH-dependent substrate specificity of cathepsin B","volume":"12","author":"Ruzza","year":"2006","journal-title":"J. Pept. Sci. Off. Publ. Eur. Pept. Soc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1046\/j.1432-1327.2000.01458.x","article-title":"Fluorescent microplate assay for cancer cell-associated cathepsin B","volume":"267","author":"Hulkower","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jconrel.2007.08.016","article-title":"Liberation of doxorubicin from HPMA copolymer conjugate is essential for the induction of cell cycle arrest and nuclear fragmentation in ovarian carcinoma cells","volume":"124","author":"Malugin","year":"2007","journal-title":"J. Control. Release"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jconrel.2008.01.003","article-title":"Doxorubicin release is not a prerequisite for the in vitro cytotoxicity of HPMA-based pharmaceuticals: In vitro effect of extra drug-free GlyPheLeuGly sequences","volume":"127","author":"Rihova","year":"2008","journal-title":"J. Control. Release"},{"key":"ref_43","first-page":"83","article-title":"Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I\/II Committee","volume":"5","author":"Vasey","year":"1999","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.progpolymsci.2005.09.004","article-title":"Polymer-drug conjugates: Progress in polymeric prodrugs","volume":"31","author":"Khandare","year":"2006","journal-title":"Prog. Polym. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ejpb.2010.07.008","article-title":"Spectral analysis of doxorubicin accumulation and the indirect quantification of its DNA intercalation","volume":"76","author":"Hovorka","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_46","first-page":"2467","article-title":"Mechanism of specific nuclear transport of adriamycin: The mode of nuclear translocation of adriamycin-proteasome complex","volume":"61","author":"Kiyomiya","year":"2001","journal-title":"Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"26584","DOI":"10.1038\/srep26584","article-title":"Engineering a 3D microfluidic culture platform for tumor-treating field application","volume":"6","author":"Pavesi","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/cyto.a.20896","article-title":"Quantifying colocalization by correlation: The Pearson correlation coefficient is superior to the Mander\u2019s overlap coefficient","volume":"77","author":"Adler","year":"2010","journal-title":"Cytometry A"},{"key":"ref_50","first-page":"227","article-title":"Flow Microfluorometric Analysis of Nuclear-DNA in Cells from Solid Tumors and Cell-Suspensions\u2014New Method for Rapid Isolation and Staining of Nuclei","volume":"24","author":"Vindelov","year":"1977","journal-title":"Virchows Arch. B"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/18\/4285\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:11:20Z","timestamp":1760177480000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/18\/4285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,18]]},"references-count":50,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["molecules25184285"],"URL":"https:\/\/doi.org\/10.3390\/molecules25184285","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,18]]}}}